OS Therapies initiates commercial manufacturing of OST-HER2

OS Therapies (OSTX) announced that it has entered into agreements for the commercial manufacture of OST-HER2. The company is currently organizing additional data in relation to the recently-completed treatment phase of its Phase 2b trial of OST-HER2 in the prevention of recurrence of lung metastatic osteosarcoma in preparation for a Type B or Type C meeting with the FDA. Following the FDA meeting, the company anticipates that it will be submitting a biologics licensing authorization application to the FDA for accelerated or conditional approval consideration.